Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors
Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
This is a phase 1 dose-escalation study to determine the maximum tolerated dose of the PARP
inhibitor olaparib in combination with PRRT in patients with a well-differentiated advanced
gastroenteropancreatic NET (GEP NET), progressive after PRRT. As secondary objectives,
efficacy, pharmacokinetics and biomarker response will be investigated.